Elan Announces the Appointment of a New Board Director

DUBLIN, Ireland--(BUSINESS WIRE)--May 26, 2006
Elan Corporation, plc today announced the appointment of
Mr. William R. Rohn to the company's Board of Directors. 
Elan's chairman, Kyran McLaughlin, said, "The Board is extremely
pleased to announce the appointment of Bill. His extensive experience
in the pharmaceutical and biotech industries, together with his
personal qualities, will make him an excellent addition to the Board
and we all look forward to working with him". 
Kelly Martin, Elan's president and chief executive officer, added:
"I look forward to working with Bill and benefiting from the
experience he brings with him". 
Mr. Rohn (62) is an experienced biotech and pharmaceutical
industry executive. He is currently Vice Chairman of Raven
Biotechnologies, Inc., and a Director of Metabasis Therapeutics, Inc.,
Cerus Corp and Pharmacyclics, Inc. Previously he was Chief Operating
Officer of Biogen Idec until January 2005 and prior thereto President
and Chief Operating Officer of Idec Pharmaceutical Corporation from
1993. 
About Elan 
Elan Corporation, plc is a neuroscience-based biotechnology
company committed to making a difference in the lives of patients and
their families by dedicating itself to bringing innovations in science
to fill significant unmet medical needs that continue to exist around
the world. Elan shares trade on the New York, London and Dublin Stock
Exchanges. For additional information about the company, please visit
http://www.elan.com. 
CONTACT:
Elan Corporation, plc
Investor Relations:                         
Emer Reynolds, 353-1-709-4000                          
or
Chris Burns, 800-252-3526                            
or
Media Relations:                
Davia Temin, 212-407-5740                
or
Elizabeth Headon, 353-1-498-0300